Country: United States
Language: English
Source: NLM (National Library of Medicine)
ETODOLAC (UNII: 2M36281008) (ETODOLAC - UNII:2M36281008)
Eon Labs, Inc.
ETODOLAC
ETODOLAC 400 mg
ORAL
PRESCRIPTION DRUG
Carefully consider the potential benefits and risks of etodolac tablets and other treatment options before deciding to use etodolac tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Etodolac tablets are indicated: Etodolac is contraindicated in patients with known hypersensitivity to etodolac or other ingredients in etodolac. Etodolac should not be given to patients who have experienced asthma, urticaria or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see WARNINGS , Anaphylactoid Reactions and PRECAUTIONS , Pre-existing Asthma ). Etodolac is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS ).
Etodolac Tablets USP, for oral administration, are available as: 400 mg : White, oval, unscored, film-coated tablets, debossed “E 140” on one side and plain on the other side and supplied as: NDC 0185-0675-01 bottles of 100 NDC 0185-0675-05 bottles of 500 NDC 0185-0675-10 bottles of 1000 500 mg : White, oval, unscored, film-coated tablets, debossed “E 139” on one side and plain on the other side and supplied as: NDC 0185-0687-01 bottles of 100 NDC 0185-0687-05 bottles of 500 NDC 0185-0687-10 bottles of 1000 Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature]. Store tablets in original container until ready to use. KEEP TIGHTLY CLOSED. Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required. KEEP OUT OF THE REACH OF CHILDREN.
Abbreviated New Drug Application
ETODOLAC- etodolac tablet, coated Eon Labs, Inc. ---------- Medication Guide FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) ETODOLAC TABLETS, USP (ee-toe-DOE-lak) What is the most important information I should know about medicines called Non-Steroidal Anti- Inflammatory Drugs (NSAIDs)? NSAIDs can cause serious side effects, including: • Increased risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase: o with increasing doses of NSAIDs o with longer use of NSAIDs Do not take NSAIDs right before or after a heart surgery called a “coronary artery bypass graft (CABG).” Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack. • Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines: o anytime during use o without warning symptoms o that may cause death The risk of getting an ulcer or bleeding increases with: o past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs o taking medicines called “corticosteroids”, “anticoagulants”, “SSRIs”, or “SNRIs” o increasing doses of NSAIDs o older age o longer use of NSAIDs o poor health o smoking o advanced liver disease o drinking alcohol o bleeding problems NSAIDs should only be used: o exactly as prescribed o at the lowest dose possible for your treatment o for the shortest time needed What are NSAIDs? NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of short-term pain. Who should not take NSAIDs? Do not take NSAIDs: • if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs. • right before or after heart bypass surgery. Before taking NSAIDs, tell your healthcare prov Read the complete document
ETODOLAC- ETODOLAC TABLET, COATED EON LABS, INC. ---------- ETODOLAC TABLETS, USP RX ONLY CARDIOVASCULAR THROMBOTIC EVENTS • • GASTROINTESTINAL RISK • DESCRIPTION Etodolac tablets, USP are a member of the pyranocarboxylic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each tablet contains etodolac, USP for oral administration. Etodolac, USP is a racemic mixture of [+]S and [-]R-enantiomers. Etodolac, USP is a white crystalline compound, insoluble in water but soluble in alcohols, chloroform, dimethyl sulfoxide, and aqueous polyethylene glycol. The chemical name is (±) 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid. The molecular weight of the base is 287.37. It has a pKa of 4.65 and an n- octanol:water partition coefficient of 11.4 at pH 7.4. The molecular formula for etodolac is C H NO and it has the following structural formula: Each tablet, for oral administration contains 400 mg and 500 mg of etodolac, USP. In Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS and PRECAUTIONS). Etodolac tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS and WARNINGS). NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal (GI) events (see WARNINGS). 17 21 3 addition, each tablet contains the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, sodium starch glycolate (potato), talc and titanium dioxide. CLINICAL PHARMACOLOGY PHARMACODYNAMICS Etodolac is a nonsteroidal anti-inflamm Read the complete document